Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup.

Autor: Creutzberg CL; Department of Radiation Oncology, Leiden University Medical Center, Leiden, Netherlands. Electronic address: c.l.creutzberg@lumc.nl., Kim JW; Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, South Korea., Eminowicz G; Department of Clinical Oncology, University College London Hospital, London, UK., Allanson E; Division of Obstetrics and Gynaecology, Medical School, University of Western Australia, Perth, WA, Australia., Eberst L; Department of Medical Oncology, Institut de Cancérologie de Strasbourg, Strasbourg, France., Kim SI; Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, South Korea., Nout RA; Department of Radiation Oncology, Erasmus Medical Center, Rotterdam, Netherlands., Park JY; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea., Lorusso D; Gynecologic Oncology Unit, Humanitas San Pio X, Milan, Italy; Humanitas University Rozzano, Milan, Italy., Mileshkin L; Department of Medical Oncology, Peter MacCallum Cancer Centre and University of Melbourne, VIC, Australia., Ottevanger PB; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands., Brand A; Department of Gynaecological Oncology, Westmead Hospital and University of Sydney, Sydney, NSW, Australia., Mezzanzanica D; Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Oza A; Division of Medical Oncology and Hematology, UHN - Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada., Gebski V; NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia., Pothuri B; Perlmutter Cancer Center, NYU Langone Health, New York, NJ, USA; Diversity and Health Equity for Clinical Trials, GOG-Foundation, Philadelphia, PA USA., Batley T; Ko Ngai Tūhoe te iwi, Kaitauwhiro Mātātahi Mokopuna Ora, Te Pūtahitanga o Te Waipounamu, Christchurch, New Zealand., Gordon C; Canadian Cancer Trials Group, London, ON, Canada., Mitra T; Kolkata Gynecological Oncology Trials and Translational Research Group (KolGOTrg), New Town, Kolkata, India., White H; Peaches Womb Cancer Trust, Manchester, UK; Cancer Research Advocates Forum, London, UK., Howitt B; Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA., Matias-Guiu X; Department of Pathology, Hospital U de Bellvitge, University of Barcelona, Barcelona, Spain; Department of Pathology, Hospital U Arnau de Vilanova, University of Lleida, Lleida, Spain., Ray-Coquard I; Centre Leon Berard and Université Claude Bernard, Lyon, France., Gaffney D; Huntsman Cancer Institute, Department of Radiation Oncology, University of Utah, Salt Lake City, UT, USA., Small W Jr; Department of Radiation Oncology, Stritch School of Medicine, Cardinal Bernadin Cancer Center, Loyola University Chicago, Maywood, IL, USA., Miller A; Department of Biostatistics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Concin N; Department of Gynaecology and Gynaecological Oncology, Medical University of Vienna, Vienna, Austria; Department of Obstetrics and Gynaecology, Medical University of Innsbruck, Innsbruck, Austria., Powell MA; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine, St Louis, MO, USA., Stuart G; Department of Obstetrics and Gynecology, University of British Colombia, Vancouver, BC, Canada., Bookman MA; Kaiser Permanente Northern California, San Francisco, CA, USA.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2024 Sep; Vol. 25 (9), pp. e420-e431.

Variability of treatment of locally advanced cervical cancer: How French multidisciplinary teams follow European guidelines?

Autor: Sabah J; Department of Breast Surgery, European Institute of Cancerology - ICANS, Strasbourg, 2. CHU de Strasbourg, Grand Est, FR, France. Electronic address: jonathan_sabah@yahoo.com., Menoux I; Department of Radiotherapy, European Institute of Cancerology ICANS, Strasbourg, France. Electronic address: i.menoux@icans.eu., Eberst L; ICANS, Strasbourg, France. Electronic address: l.eberst@icans.eu., Lodi M; Department of Breast Surgery, European Institute of Cancerology - Strasbourg, ICANS, France. Electronic address: m.lodi@icans.eu., Gantzer J; ICANS, Strasbourg, France. Electronic address: j.gantzer@icans.eu., Azais H; Hopital Europeen Georges Pompidou, Gynecologic and Breast Oncologic Surgery, 20 rue Leblanc, Paris, Île-de-France, FR, 75015, France. Electronic address: henri.azais@aphp.fr., El Hajj H; Curie Institute Hospital Group, Oncologic Surgery Paris, Île-de-France, FR, France. Electronic address: houssein-elhajj@outlook.com., Balaya V; Hopital Europeen Georges Pompidou, Service de Chirurgie Gynecologique, Cancerologique et du Sein, 25 Rue de Coulmiers, Paris, FR, 75014, France. Electronic address: vbalaya@hotmail.com., Babin G; Institut Bergonié, Department of Surgery, Bordeaux, FR, 33076, France. Electronic address: g.babin@bordeaux.unicancer.fr., Espenel S; Département de Radiothérapie, Gustave-Roussy, 114, rue Édouard-Vaillant, 94805, Villejuif, France. Electronic address: sophie.espenel@gustaveroussy.fr., Dabi Y; Assistance Publique - Hopitaux de Paris, Gynecologic Oncology, 4 rue de la Chine, Paris, FR, 75184, France. Electronic address: yohann.dabi@gmail.com., Kissel M; Institut Curie Radiation Oncology Department, Paris, Curie Institute Hospital Group, Radiotherapy, Paris, Île-de-France, FR, France. Electronic address: manonkissel@hotmail.com., Phuong Lien T; University Hospital Reunion South Sites Saint-Pierre, Gynecology Obstetrics Avenue François Mitterrand, Saint-Pierre, RE, 97448, France. Electronic address: phuong.tran@chu-reunion.fr., Angeles MA; Institut Universitaire du Cancer Toulouse Oncopole, Department of Surgical Oncology 1, Avenue Irène Joliot-Curie, Toulouse, FR, 31100, France. Electronic address: martinangeles22@hotmail.com., Margueritte F; Centre Hospitalier Universitaire de Limoges, Gynecology and Obstetrics, 8 Avenue Dominique Larrey, Limoges, FR, 87000, France. Electronic address: fmargueritte@gmail.com., Deluche E; Centre Hospitalier Universitaire de Limoges, Oncologie Médicale, Limoges, FR, France. Electronic address: elise.DELUCHE@chu-limoges.fr., Marouk A; Emergency Department, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris, Paris, France. Electronic address: alexis.marouk@aphp.fr., Le Borgne P; Structure des Urgences, Hôpitaux Universitaires de Strasbourg, 67000, Strasbourg, France. Electronic address: pierrick.leborgne@chru-strasbourg.fr., Apithy MS; Chirurgie Oncologique, Cotonou, Littoral, Benin. Electronic address: msapithy@gmail.com., Laas-Faron E; Curie Institute Hospital Group, Chirurgie Senologique, Gynécologique et Reconstructrice Paris, Île-de-France, FR, France. Electronic address: enora.laas@curie.fr., Akladios C; Hôpitaux Universitaires de Strasbourg, Department of Gynecology Strasbourg, FR, 67091, France. Electronic address: cherif.akladios@chru-strasbourg.fr., Lecointre L; CHRU de Strasbourg | CHRU Strasbourg Chirurgie Gynécologique, Pôle Gynécologie-Obstétrique, Institute of Image Guided Surgery, IHU-Strasbourg, France; ICube, Laboratoire des Sciences de l'Ingérnieur de l'Informatique et de l'Imagerie, France. Electronic address: lise.lecointre@chru-strasbourg.fr.

Publikováno v: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology [Eur J Surg Oncol] 2024 Jun; Vol. 50 (6), pp. 108281. Date of Electronic Publication: 2024 Mar 29.

The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers.

Autor: Voissière A; Université Claude Bernard Lyon 1, INSERM U-1052, CNRS 5286, Cancer Research Center of Lyon, Lyon, France., Gomez-Roca C; Department of Medical Oncology, Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France., Chabaud S; Clinical Research Platform (DRCI), Centre Léon Bérard, Lyon, France., Rodriguez C; Université Claude Bernard Lyon 1, INSERM U-1052, CNRS 5286, Cancer Research Center of Lyon, Lyon, France.; Lyon Immunotherapy for Cancer Laboratory (LICL), Centre Léon Bérard, Lyon, France., Nkodia A; Lyon Immunotherapy for Cancer Laboratory (LICL), Centre Léon Bérard, Lyon, France., Berthet J; Université Claude Bernard Lyon 1, INSERM U-1052, CNRS 5286, Cancer Research Center of Lyon, Lyon, France.; Lyon Immunotherapy for Cancer Laboratory (LICL), Centre Léon Bérard, Lyon, France., Montane L; Clinical Research Platform (DRCI), Centre Léon Bérard, Lyon, France., Bidaux AS; Clinical Research Platform (DRCI), Centre Léon Bérard, Lyon, France., Treilleux I; Biopathology Department, Centre Léon Bérard, Lyon, France., Eberst L; Department of Medical Oncology, Centre Léon Bérard, 28 rue Laennec, Lyon, France., Terret C; Department of Medical Oncology, Centre Léon Bérard, 28 rue Laennec, Lyon, France., Korakis I; Department of Medical Oncology, Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France., Garin G; Clinical Research Platform (DRCI), Centre Léon Bérard, Lyon, France., Pérol D; Clinical Research Platform (DRCI), Centre Léon Bérard, Lyon, France., Delord JP; Department of Medical Oncology, Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France., Caux C; Université Claude Bernard Lyon 1, INSERM U-1052, CNRS 5286, Cancer Research Center of Lyon, Lyon, France.; Lyon Immunotherapy for Cancer Laboratory (LICL), Centre Léon Bérard, Lyon, France., Dubois B; Université Claude Bernard Lyon 1, INSERM U-1052, CNRS 5286, Cancer Research Center of Lyon, Lyon, France.; Lyon Immunotherapy for Cancer Laboratory (LICL), Centre Léon Bérard, Lyon, France., Ménétrier-Caux C; Université Claude Bernard Lyon 1, INSERM U-1052, CNRS 5286, Cancer Research Center of Lyon, Lyon, France.; Lyon Immunotherapy for Cancer Laboratory (LICL), Centre Léon Bérard, Lyon, France., Bendriss-Vermare N; Université Claude Bernard Lyon 1, INSERM U-1052, CNRS 5286, Cancer Research Center of Lyon, Lyon, France.; Lyon Immunotherapy for Cancer Laboratory (LICL), Centre Léon Bérard, Lyon, France., Cassier PA; Department of Medical Oncology, Centre Léon Bérard, 28 rue Laennec, Lyon, France.

Publikováno v: Science translational medicine [Sci Transl Med] 2024 Jan 24; Vol. 16 (731), pp. eadd1834. Date of Electronic Publication: 2024 Jan 24.

Clinical outcome of patients with isolated central nervous system progression on first-line pertuzumab and trastuzumab treatment for HER2-positive metastatic breast cancer in a real-life cohort.

Autor: Collet L; Department of Medical Oncology Centre Léon Bérard, 28 Avenue Laënnec, 69008, Lyon, France., Eberst L; Department of Medical Oncology, Institut de Cancérologie de Strasbourg, Strasbourg, France., Ludovic G; Department of Statistics, Institut de Cancérologie de Montpellier, Montpellier, France., Debled M; Department of Medical Oncology, Institut Bergonié, Bordeaux, France., Hrab L; Department of Medical Oncology, Centre François Baclesse, Caen, France., Mouret-Reynier MA; Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France., Desmoulins I; Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France., Goncalves A; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France., Campone M; Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Angers & Nantes, France., Ferrero JM; Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France., Brain E; Department of Medical Oncology, Institut Curie, Paris and Saint-Cloud, France., Uwer L; Department of Medical Oncology, Institut de Cancérologie de Lorraine, Nancy, France., Eymard JC; Department of Medical Oncology, Institut Jean Godinot, Reims, France., Dieras V; Department of Medical Oncology, Centre Eugène Marquis, Rennes, France., Simon G; Real Word Data Department, Data Office, Unicancer, Paris, France., Leheurteur M; Department of Medical Oncology, Centre Henri Becquerel, Rouen, France., Dalenc F; Department of Medical Oncology, Institut Claudius Regaud, Toulouse, France., Vanlemmens L; Department of Medical Oncology, Centre Oscar Lambret, Lille, France., Darlix A; Department of Medical Oncology, Institut Régional du Cancer de Montpellier, Institut de Génomique Fonctionnelle, INSERM, CNRS, University of Montpellier, Montpellier, France., Arnedos M; Department of Medical Oncology, Institut Bergonié, Bordeaux, France.; Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France., Bachelot T; Department of Medical Oncology Centre Léon Bérard, 28 Avenue Laënnec, 69008, Lyon, France. thomas.bachelot@lyon.unicancer.fr.

Publikováno v: Breast cancer (Tokyo, Japan) [Breast Cancer] 2023 Mar; Vol. 30 (2), pp. 329-341. Date of Electronic Publication: 2023 Jan 11.

736P Exceptional clinical benefit (ECB) from immune checkpoint inhibitors (ICIs) in mismatch-repair deficient (MMRd) in recurrent /metastatic endometrial cancer (r/mEC): Are we curing a subset of MMRd EC patients (pts)?

Autor: Béjar, J.F. Grau, Guinel, T., Mazzeo, R., Musacchio, L., Le Saux, O., Sabatier, R., Salaun, H., Eberst, L., Duran, C. Garcia, Carità, L., Villacampa, G., Frenel, J-S., Scambia, G., Ray-Coquard, I., Lorusso, D., Oaknin, A., Leary, A.

Publikováno v: In Annals of Oncology September 2024 35 Supplement 2:S560-S560